High-throughput sequencing technology in the identification of B cell abnormalities in systemic lupus erythematosus
10.3760/cma.j.cn112309-20230926-00091
- VernacularTitle:高通量测序揭示系统性红斑狼疮B细胞异常的研究进展
- Author:
Yanqi XIA
1
;
Han ZHAO
;
Luo DUAN
;
Huihui YUAN
Author Information
1. 首都医科大学基础医学院免疫学系，北京 100069
- Keywords:
Systemic lupus erythematosus;
High-throughput sequencing;
B cell subsets;
B cell receptors;
Autoimmunity
- From:
Chinese Journal of Microbiology and Immunology
2024;44(7):641-645
- CountryChina
- Language:Chinese
-
Abstract:
Systemic lupus erythematosus (SLE) is an acute or chronic autoimmune disease characterized by the presence of pathogenic autoantibodies and immune complexes, and multiorgan damage. It is a highly heterogeneous disease and commonly developed in women of childbearing age. The cause of systemic immunopathological injury in SLE is due to the production of autoantibodies by overactivated autoreactive B cells. The treatment of SLE by targeting B cells is very effective, suggesting the critical role of B cells in the development and progression of SLE. However, the current B cell depletion therapies all target the total B cell population, which are not capable of clearing specifically autoreactive B cells since the specific marker molecules and the mechanisms associated with the development of SLE remain unclear. With the development of science and technology, high-throughput sequencing technology provides new ideas for the study of B cell abnormalities in SLE. This review focuses on the progress in high-throughput sequencing to reveal new abnormalities in B cell receptors, new B cell subsets and B cell-related novel therapeutic targets, hoping to provide reference for better understanding the pathogenesis and exploring therapeutic strategies.
